Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Liabilities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Total Liabilities for 4 consecutive years, with $66.7 million as the latest value for Q4 2025.

  • For Q4 2025, Total Liabilities fell 16.71% year-over-year to $66.7 million; the TTM value through Dec 2025 reached $66.7 million, down 16.71%, while the annual FY2025 figure was $66.7 million, 16.71% down from the prior year.
  • Total Liabilities was $66.7 million for Q4 2025 at Day One Biopharmaceuticals, up from $62.9 million in the prior quarter.
  • The five-year high for Total Liabilities was $93.7 million in Q2 2024, with the low at $8.2 million in Q1 2022.
  • Historically, Total Liabilities has averaged $40.7 million across 4 years, with a median of $29.7 million in 2023.
  • The largest annual shift saw Total Liabilities soared 279.35% in 2024 before it crashed 37.89% in 2025.
  • Over 4 years, Total Liabilities stood at $17.0 million in 2022, then soared by 73.34% to $29.5 million in 2023, then soared by 171.24% to $80.0 million in 2024, then fell by 16.71% to $66.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $66.7 million in Q4 2025, $62.9 million in Q3 2025, and $58.2 million in Q2 2025.